← Leaderboards
Nupam P Mahajan
Washington University
$8,775,560
Attributed
$11,370,354
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,370,354 · 7
By mechanism
R01$11,370,354 · 7
Top collaborators
- Felix Yi-Chung Feng5 shared
- Kiran N Mahajan4 shared
Most similar at Washington University
Same institution · by research overlap
- David Wang$34,713,611
- Jeffrey D Milbrandt$49,168,006
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateTumor GrowthResistancePhosphorylationAck1 GenePhosphotransferasesAndrogen ReceptorAbirateroneProstateAblationProtein Tyrosine KinaseProstate Cancer ModelCellsExhibitsSmall Molecule InhibitorEpigenetic ProcessGenetic TranscriptionCancer PatientResistance DevelopmentGenerationsSignal TransductionDepositionAndrogen Deprivation TherapyCessation Of Life
Grant awards (25)
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer$643,764
R01 · FY2025 · CA · contact PI
Regulation of Androgen Receptor by NXTAR Long non-coding RNA in Prostate Cancer and its Therapeutic Implications$530,267
R01 · FY2025 · CA · contact PI
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate Cancer$484,365
R01 · FY2025 · CA · contact PI
Regulation of Mitochondrial Metabolism by Tyr-phosphorylated ATP Synthase Alpha-Subunit and its Therapeutic Implications in Prostate Cancer$462,560
R01 · FY2025 · CA · contact PI
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer$652,414
R01 · FY2024 · CA · contact PI
Regulation of Androgen Receptor by NXTAR Long non-coding RNA in Prostate Cancer and its Therapeutic Implications$549,357
R01 · FY2024 · CA · contact PI
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate Cancer$460,148
R01 · FY2024 · CA · contact PI
Regulation of Mitochondrial Metabolism by Tyr-phosphorylated ATP Synthase Alpha-Subunit and its Therapeutic Implications in Prostate Cancer$439,433
R01 · FY2024 · CA · contact PI
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$651,939
R01 · FY2023 · CA · contact PI
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate Cancer$484,364
R01 · FY2023 · CA · contact PI
Regulation of Mitochondrial Metabolism by Tyr-phosphorylated ATP Synthase Alpha-Subunit and its Therapeutic Implications in Prostate Cancer$477,966
R01 · FY2023 · CA · contact PI
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$598,615
R01 · FY2022 · CA · contact PI
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$533,911
R01 · FY2021 · CA · contact PI
Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer$338,664
R01 · FY2021 · CA · contact PI
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$505,524
R01 · FY2020 · CA · contact PI
Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer$338,306
R01 · FY2020 · CA · contact PI
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies$523,797
R01 · FY2019 · CA · contact PI
Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer$326,418
R01 · FY2019 · CA · contact PI
Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer$369,843
R01 · FY2018 · CA · contact PI
Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer$369,843
R01 · FY2017 · CA · contact PI
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer$314,143
R01 · FY2014 · CA · contact PI
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer$304,764
R01 · FY2013 · CA · contact PI
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer$328,495
R01 · FY2012 · CA · contact PI
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer$328,873
R01 · FY2011 · CA · contact PI
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer$352,581
R01 · FY2010 · CA · contact PI